US5643567A
(en)
*
|
1990-12-04 |
1997-07-01 |
Board Of Regents, The University Of Texas System |
Methods for the suppression of neu mediated tumors by adenoviral E1A and SV40 large T antigen
|
US5641484A
(en)
*
|
1990-12-04 |
1997-06-24 |
Board Of Regents, The University Of Texas System |
Methods for the suppression of neu mediated tumors by adenoviral E1A and SV40 large T antigen
|
ES2093248T3
(es)
*
|
1990-12-04 |
1996-12-16 |
Univ Texas |
Metodos y composiciones para la supresion de la transformacion mediada por el neu.
|
US5747469A
(en)
|
1991-03-06 |
1998-05-05 |
Board Of Regents, The University Of Texas System |
Methods and compositions comprising DNA damaging agents and p53
|
US6410010B1
(en)
|
1992-10-13 |
2002-06-25 |
Board Of Regents, The University Of Texas System |
Recombinant P53 adenovirus compositions
|
EP0575518A1
(de)
|
1991-03-06 |
1993-12-29 |
Board Of Regents, The University Of Texas System |
Verfahren und zusammensetzungen fuer die selektive hemmung von genexpression
|
AU675948B2
(en)
*
|
1992-05-01 |
1997-02-27 |
United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The |
Bystander effect tumoricidal therapy
|
CA2592997A1
(en)
*
|
1992-12-03 |
1994-06-09 |
Genzyme Corporation |
Pseudo-adenovirus vectors
|
FR2704234B1
(fr)
*
|
1993-04-22 |
1995-07-21 |
Centre Nat Rech Scient |
Virus recombinants, preparation et utilisation en therapie genique.
|
FR2704556B1
(fr)
*
|
1993-04-30 |
1995-07-13 |
Rhone Poulenc Rorer Sa |
Virus recombinants et leur utilisation en thérapie génique.
|
EP1211319A2
(de)
*
|
1993-05-10 |
2002-06-05 |
The Regents of The University of Michigan |
Gentransfer zu den pankreatischen und Gallenepithelialzellen
|
JPH08511423A
(ja)
|
1993-06-10 |
1996-12-03 |
ジェネティック セラピー,インコーポレイテッド |
血友病治療のためのアデノウイルスベクター
|
US5645829A
(en)
*
|
1993-06-18 |
1997-07-08 |
Beth Israel Hospital Association |
Mesothelial cell gene therapy
|
US7252989B1
(en)
|
1994-04-04 |
2007-08-07 |
Board Of Regents, The University Of Texas System |
Adenovirus supervector system
|
WO1995029993A1
(en)
*
|
1994-04-28 |
1995-11-09 |
The University Of Michigan |
Gene delivery vector using plasmid dna packaged into an adenovirus and a packaging cell line
|
US6465253B1
(en)
|
1994-09-08 |
2002-10-15 |
Genvec, Inc. |
Vectors and methods for gene transfer to cells
|
US5846782A
(en)
*
|
1995-11-28 |
1998-12-08 |
Genvec, Inc. |
Targeting adenovirus with use of constrained peptide motifs
|
WO1996013597A2
(en)
*
|
1994-10-28 |
1996-05-09 |
The Trustees Of The University Of Pennsylvania |
Improved adenovirus and methods of use thereof
|
US6326356B1
(en)
|
1996-10-18 |
2001-12-04 |
Board Of Regents, The University Of Texas System |
Suppression of neu overexpression using a mini-E1A gene
|
US5843742A
(en)
*
|
1994-12-16 |
1998-12-01 |
Avigen Incorporated |
Adeno-associated derived vector systems for gene delivery and integration into target cells
|
WO1996020732A2
(en)
*
|
1994-12-30 |
1996-07-11 |
Chiron Corporation |
Non-traumatic administration of gene delivery vehicles
|
US5637456A
(en)
*
|
1995-02-17 |
1997-06-10 |
The University Of Texas, Board Of Regents |
Rapid test for determining the amount of functionally inactive gene in a gene therapy vector preparation
|
US5770442A
(en)
*
|
1995-02-21 |
1998-06-23 |
Cornell Research Foundation, Inc. |
Chimeric adenoviral fiber protein and methods of using same
|
US6127525A
(en)
*
|
1995-02-21 |
2000-10-03 |
Cornell Research Foundation, Inc. |
Chimeric adenoviral coat protein and methods of using same
|
FR2732978B1
(fr)
|
1995-04-14 |
1997-05-30 |
Inst Nat Sante Rech Med |
Vecteur viral recombinant, composition pharmaceutique le contenant et cellules transformees correspondantes
|
KR19990022184A
(ko)
*
|
1995-06-07 |
1999-03-25 |
스톤 스티븐 에프. |
유전자구성물의 경구투여
|
US6783980B2
(en)
|
1995-06-15 |
2004-08-31 |
Crucell Holland B.V. |
Packaging systems for human recombinant adenovirus to be used in gene therapy
|
EP0894139A1
(de)
|
1996-03-20 |
1999-02-03 |
Board Of Regents The University Of Texas System |
Sensibilisierung von her-2/neu überexprimirenden krebszellen zur chemotherapie
|
FR2748753B1
(fr)
*
|
1996-05-20 |
1998-08-14 |
Transgene Sa |
Nouveaux vecteurs adenoviraux pour la therapie genique
|
US5958892A
(en)
|
1996-07-30 |
1999-09-28 |
Board Of Regents, The University Of Texas System |
2-methoxyestradiol-induced apoptosis in cancer cells
|
US6225290B1
(en)
*
|
1996-09-19 |
2001-05-01 |
The Regents Of The University Of California |
Systemic gene therapy by intestinal cell transformation
|
GB2318732A
(en)
|
1996-11-01 |
1998-05-06 |
Johnson & Johnson Medical |
Wound healing compositions containing alpha-1-antitrypsin
|
US6710036B2
(en)
|
1997-07-25 |
2004-03-23 |
Avigen, Inc. |
Induction of immune response to antigens expressed by recombinant adeno-associated virus
|
BR9813930A
(pt)
|
1997-11-06 |
2006-12-19 |
Chiron Spa |
antìgeno neisserial
|
DK1047784T4
(en)
|
1998-01-14 |
2015-06-15 |
Novartis Vaccines & Diagnostic |
NEISSERA meningitidis ANTIGENS
|
US20020147143A1
(en)
|
1998-03-18 |
2002-10-10 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
EP2261345A3
(de)
|
1998-05-01 |
2012-01-11 |
Novartis Vaccines and Diagnostics, Inc. |
Antigene und Zusammensetzungen gegen Neisseria meningitidis
|
JPH11335269A
(ja)
|
1998-05-19 |
1999-12-07 |
Hisamitsu Pharmaceut Co Inc |
遺伝子関連医薬の経口投与固形製剤
|
US20030017138A1
(en)
|
1998-07-08 |
2003-01-23 |
Menzo Havenga |
Chimeric adenoviruses
|
US20030235557A1
(en)
|
1998-09-30 |
2003-12-25 |
Corixa Corporation |
Compositions and methods for WT1 specific immunotherapy
|
US6200560B1
(en)
|
1998-10-20 |
2001-03-13 |
Avigen, Inc. |
Adeno-associated virus vectors for expression of factor VIII by target cells
|
US6221349B1
(en)
|
1998-10-20 |
2001-04-24 |
Avigen, Inc. |
Adeno-associated vectors for expression of factor VIII by target cells
|
US6929946B1
(en)
|
1998-11-20 |
2005-08-16 |
Crucell Holland B.V. |
Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
|
AU2221600A
(en)
|
1998-12-31 |
2000-07-31 |
Chiron Corporation |
Improved expression of hiv polypeptides and production of virus-like particles
|
US7935805B1
(en)
|
1998-12-31 |
2011-05-03 |
Novartis Vaccines & Diagnostics, Inc |
Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
|
ES2477194T3
(es)
|
1999-04-30 |
2014-07-16 |
Novartis Vaccines And Diagnostics S.R.L. |
Ant�genos neisseriales conservados
|
US6492169B1
(en)
|
1999-05-18 |
2002-12-10 |
Crucell Holland, B.V. |
Complementing cell lines
|
US6913922B1
(en)
|
1999-05-18 |
2005-07-05 |
Crucell Holland B.V. |
Serotype of adenovirus and uses thereof
|
GB9911683D0
(en)
|
1999-05-19 |
1999-07-21 |
Chiron Spa |
Antigenic peptides
|
WO2001000663A2
(en)
|
1999-06-28 |
2001-01-04 |
Oklahoma Medical Research Foundation |
Catalytically active recombinant memapsin and methods of use thereof
|
GB9916529D0
(en)
|
1999-07-14 |
1999-09-15 |
Chiron Spa |
Antigenic peptides
|
US6410236B1
(en)
|
1999-09-01 |
2002-06-25 |
The Regents Of The University Of Michigan |
Correcting diastolic dysfunction in heart failure
|
GB9924981D0
(en)
|
1999-10-21 |
1999-12-22 |
Univ Manchester |
Gene therapy
|
EP2975127A1
(de)
|
1999-10-29 |
2016-01-20 |
GlaxoSmithKline Biologicals SA |
Neisseria antigenpeptide
|
CA2392103A1
(en)
|
1999-11-18 |
2001-05-25 |
Chiron Corporation |
Human fgf-21 gene and gene expression products
|
PT1248647E
(pt)
|
2000-01-17 |
2010-11-18 |
Novartis Vaccines & Diagnostics Srl |
Vacina de vesícula da membrana externa (omv) compreendendo proteínas de membrana externa de n. meningitidis do serogrupo b
|
EP1854476A3
(de)
|
2000-02-09 |
2008-05-07 |
Bas Medical, Inc. |
Verwendung von Relaxin zur Behandlung von durch Vasokonstriktion bedingten Krankheiten
|
EP1265915B1
(de)
|
2000-02-23 |
2010-11-10 |
GlaxoSmithKline Biologicals s.a. |
Neue verbindungen
|
US20020082205A1
(en)
|
2000-03-08 |
2002-06-27 |
Nobuyuki Itoh |
Human FGF-23 gene and gene expression products
|
US7700359B2
(en)
|
2000-06-02 |
2010-04-20 |
Novartis Vaccines And Diagnostics, Inc. |
Gene products differentially expressed in cancerous cells
|
DE60134275D1
(de)
|
2000-06-15 |
2008-07-10 |
Novartis Vaccines & Diagnostic |
Polynukleotide zur bestimmung von kolonkrebs
|
EP1319069B1
(de)
|
2000-06-28 |
2008-05-21 |
Corixa Corporation |
Zusammensetzungen und verfahren für therapie und diagnose von lungenkrebs
|
AU2001271614B2
(en)
|
2000-07-03 |
2007-05-31 |
Catalent Pharma Solutions, Llc |
Host cells containing multiple integrating vectors
|
CA2413156C
(en)
|
2000-07-03 |
2009-08-18 |
Gala Design, Inc. |
Expression vectors
|
DE60138403D1
(de)
|
2000-09-26 |
2009-05-28 |
Crucell Holland Bv |
Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten
|
EP2284181A1
(de)
|
2000-10-27 |
2011-02-16 |
Novartis Vaccines and Diagnostics S.r.l. |
Nukleinsäure und Proteine von Gruppen Streptokokkengruppen A und B
|
EP2339035A1
(de)
|
2000-12-07 |
2011-06-29 |
Novartis Vaccines and Diagnostics, Inc. |
Endogene Retroviren, die in Prostatkrebs hochreguliert sind
|
DE60239317D1
(de)
|
2001-01-12 |
2011-04-14 |
Novartis Vaccines & Diagnostic |
Nukleinsäure mukosale immunisierung
|
GB0107661D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Staphylococcus aureus
|
GB0107658D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Streptococcus pneumoniae
|
AU2002258728A1
(en)
|
2001-04-06 |
2002-10-21 |
Georgetown University |
Gene brcc-3 and diagnostic and therapeutic uses thereof
|
AU2002303261A1
(en)
|
2001-04-06 |
2002-10-21 |
Georgetown University |
Gene brcc2 and diagnostic and therapeutic uses thereof
|
AU2002305151A1
(en)
|
2001-04-06 |
2002-10-21 |
Georgetown University |
Gene scc-112 and diagnostic and therapeutic uses thereof
|
WO2002089747A2
(en)
|
2001-05-09 |
2002-11-14 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of prostate cancer
|
CA2452015C
(en)
|
2001-07-05 |
2012-07-03 |
Chiron Corporation |
Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
|
EP2280074A3
(de)
|
2001-07-05 |
2011-06-22 |
Novartis Vaccines and Diagnostics, Inc. |
Antigene typ-b- und/oder typ-c-hiv-polypeptide codierende polynukleotide, polypeptide und deren verwendungen
|
US7498407B2
(en)
|
2001-11-09 |
2009-03-03 |
Georgetown University |
Vascular endothelial cell growth inhibitor, VEGI-192a
|
CN100534436C
(zh)
|
2001-11-21 |
2009-09-02 |
利兰·斯坦福青年大学托管委员会 |
多核苷酸
|
NZ533428A
(en)
|
2001-12-12 |
2008-03-28 |
Chiron Srl |
Immunisation against chlamydia trachomatis
|
ES2405790T3
(es)
|
2001-12-17 |
2013-06-03 |
Corixa Corporation |
Composiciones y métodos para la terapia y el diagnóstico de enfermedad inflamatoria del intestino
|
JP4376629B2
(ja)
|
2002-01-08 |
2009-12-02 |
ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド |
癌性胸部細胞において差次的に発現された遺伝子産物およびその使用方法
|
WO2003078453A1
(en)
|
2002-03-15 |
2003-09-25 |
Wyeth Holdings Corporation |
Mutants of the p4 protein of nontypable haemophilus influenzae with reduced enzymatic activity
|
EP1501855A4
(de)
|
2002-03-21 |
2006-02-22 |
Sagres Discovery Inc |
Neue zusammensetzungen und verfahren bei krebs
|
US20040038304A1
(en)
|
2002-03-28 |
2004-02-26 |
Gala Design, Inc. |
Antibody libraries
|
US7244565B2
(en)
|
2002-04-10 |
2007-07-17 |
Georgetown University |
Gene shinc-3 and diagnostic and therapeutic uses thereof
|
MXPA04008891A
(es)
|
2002-04-25 |
2004-11-26 |
Crucell Holland Bv |
Medios y metodos para la produccion de vectores de adenovirus.
|
EP1532161B1
(de)
|
2002-06-13 |
2012-02-15 |
Novartis Vaccines and Diagnostics, Inc. |
Vektoren zur expression von hml-2-polypeptiden
|
UA80447C2
(en)
|
2002-10-08 |
2007-09-25 |
|
Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
|
DK1569696T3
(da)
|
2002-11-21 |
2010-11-15 |
Bayhill Therapeutics Inc |
Fremgangsmåder og immunmodulatoriske nukleinsyrepræparater til forebyggelse og behandling af sygdomme
|
US7569364B2
(en)
|
2002-12-24 |
2009-08-04 |
Pfizer Inc. |
Anti-NGF antibodies and methods using same
|
US9498530B2
(en)
|
2002-12-24 |
2016-11-22 |
Rinat Neuroscience Corp. |
Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
|
WO2004058184A2
(en)
|
2002-12-24 |
2004-07-15 |
Rinat Neuroscience Corp. |
Anti-ngf antibodies and methods using same
|
DK1589934T3
(en)
|
2003-01-06 |
2015-12-21 |
Corixa Corp |
Certain AMINOAL COOLER GLUCOSAMINIDE PHOSPHATE COMPOUNDS AND APPLICATION
|
US7960522B2
(en)
|
2003-01-06 |
2011-06-14 |
Corixa Corporation |
Certain aminoalkyl glucosaminide phosphate compounds and their use
|
US20040170982A1
(en)
|
2003-02-14 |
2004-09-02 |
Morris David W. |
Novel therapeutic targets in cancer
|
EP2058408A3
(de)
|
2003-02-14 |
2009-09-09 |
Sagres Discovery, Inc. |
Therapeutische GPCR-Targets für Karzinome
|
US7767387B2
(en)
|
2003-06-13 |
2010-08-03 |
Sagres Discovery, Inc. |
Therapeutic targets in cancer
|
BRPI0407375A
(pt)
|
2003-02-19 |
2006-02-07 |
Rinat Neuroscience Corp |
Métodos para tratar dor por meio da administração de um antagonista do fator de crescimento neural e u nsaid e composições contendo os mesmos
|
GB0308198D0
(en)
|
2003-04-09 |
2003-05-14 |
Chiron Srl |
ADP-ribosylating bacterial toxin
|
US20070178066A1
(en)
|
2003-04-21 |
2007-08-02 |
Hall Frederick L |
Pathotropic targeted gene delivery system for cancer and other disorders
|
ATE513471T1
(de)
|
2003-04-21 |
2011-07-15 |
Epeius Biotechnologies Corp |
Verfahren und zusammensetzungen zur behandlung von erkrankungen
|
US20070073048A1
(en)
|
2003-05-15 |
2007-03-29 |
Ying Lian |
Hiv polynucleotides and polypeptides derived from botswana mj4
|
PL1625210T3
(pl)
|
2003-05-21 |
2011-05-31 |
Genzyme Corp |
Sposoby wytwarzania preparatów rekombinowanych wirionów AAV zasadniczo niezawierających pustych kapsydów
|
US20050036988A1
(en)
*
|
2003-05-28 |
2005-02-17 |
Ruian Xu |
Compositions and methods for preventing and treating liver cirrhosis
|
US7261882B2
(en)
|
2003-06-23 |
2007-08-28 |
Reagents Of The University Of Colorado |
Methods for treating neuropathic pain by administering IL-10 polypeptides
|
KR20070001932A
(ko)
|
2003-12-23 |
2007-01-04 |
리나트 뉴로사이언스 코퍼레이션 |
작용물질 항 티알케이씨 항체 및 그의 사용 방법
|
US8268324B2
(en)
|
2004-03-29 |
2012-09-18 |
Galpharma Co., Ltd. |
Modified galectin 9 proteins and use thereof
|
KR101637908B1
(ko)
|
2004-04-07 |
2016-07-11 |
리나트 뉴로사이언스 코프. |
신경성장인자 길항제의 투여에 의한 골암 통증의 치료방법
|
EP2495252B1
(de)
|
2004-07-09 |
2018-04-18 |
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. |
Lösliche Formen von Hendra- und Nipah-Virus-G-Glycoprotein
|
US20060024677A1
(en)
|
2004-07-20 |
2006-02-02 |
Morris David W |
Novel therapeutic targets in cancer
|
KR101068289B1
(ko)
|
2004-07-30 |
2011-09-28 |
리나트 뉴로사이언스 코퍼레이션 |
아밀로이드-베타 펩티드에 대해 지시된 항체 및 이의 사용 방법
|
WO2006020684A2
(en)
|
2004-08-10 |
2006-02-23 |
Institute For Multiple Myeloma And Bone Cancer Research |
Methods of regulating differentiation and treating of multiple myeloma
|
WO2006020996A2
(en)
|
2004-08-11 |
2006-02-23 |
Cedars-Sinai Medical Center |
Treatment of parkinson's disease and related disorders
|
EP1786474B1
(de)
|
2004-08-12 |
2011-06-01 |
Cedars-Sinai Medical Center |
Kombinierte gentherapie zur behandlung makroskopischer glioma
|
BRPI0515520A
(pt)
|
2004-09-22 |
2008-07-29 |
Glaxosmithkline Biolog Sa |
composição imunogênica, vacina, métodos de preparar uma vacina e de prevenir ou tratar infecção estafilocócica, e, uso de composição imunogênica
|
AU2005294247B2
(en)
|
2004-10-05 |
2011-08-11 |
Genzyme Corporation |
Stepped cannula
|
NZ599345A
(en)
|
2005-02-18 |
2013-07-26 |
Novartis Vaccines & Diagnostic |
Immunogens from uropathogenic Escherichia Coli
|
EP1910557A2
(de)
|
2005-04-07 |
2008-04-16 |
Chiron Corporation |
Gene in verbindung mit krebs
|
EP1865981A2
(de)
|
2005-04-07 |
2007-12-19 |
Chiron Corporation |
Cacna1e in der diagnose und nachweis von sowie als therapeutisches mittel gegen krebs
|
WO2006113209A1
(en)
|
2005-04-15 |
2006-10-26 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
|
WO2006130581A2
(en)
|
2005-05-31 |
2006-12-07 |
Avigen, Inc. |
Methods for delivering genes
|
CA2615615A1
(en)
|
2005-07-22 |
2007-02-01 |
Y's Therapeutics Co., Ltd. |
Anti-cd26 antibodies and methods of use thereof
|
US7858590B2
(en)
|
2005-08-11 |
2010-12-28 |
Cedars-Sinai Medical Center |
Treatment of parkinson's disease and related disorders
|
BRPI0618705B8
(pt)
|
2005-11-14 |
2021-05-25 |
Labrys Biologics Inc |
anticorpos antagonistas humanizados direcionados contra peptídeo relacionado ao gene da calcitonina, composição farmacêutica e uso dos mesmos
|
JP5215865B2
(ja)
|
2005-11-22 |
2013-06-19 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド |
ノロウイルス抗原およびサポウイルス抗原
|
WO2007120368A2
(en)
|
2006-01-09 |
2007-10-25 |
The Regents Of The University Of California |
Immunostimulatory combinations for vaccine adjuvants
|
WO2007126959A2
(en)
|
2006-03-29 |
2007-11-08 |
Dana-Farber Cancer Institute |
Methods and compositions for inducing an immune response to hiv and models for testing
|
NZ571965A
(en)
|
2006-03-30 |
2012-02-24 |
Engene Inc |
Chitosan-based nanoparticles and methods for transfecting gut cells in vivo
|
JP5313886B2
(ja)
|
2006-06-07 |
2013-10-09 |
バイオアライアンス セー.フェー. |
癌細胞で発現するcd−43およびceaの炭水化物含有エピトープを認識する抗体およびそれを使用する方法
|
EP2054431B1
(de)
|
2006-06-09 |
2011-08-31 |
Novartis AG |
Bakterielle adhäsine konformere
|
AU2007285484B2
(en)
|
2006-08-16 |
2013-05-02 |
Novartis Ag |
Immunogens from uropathogenic Escherichia coli
|
US8685720B2
(en)
|
2006-11-03 |
2014-04-01 |
The Trustees Of Princeton University |
Engineered cellular pathways for programmed autoregulation of differentiation
|
CN1966082B
(zh)
*
|
2006-11-03 |
2010-06-30 |
许瑞安 |
一种防治结直肠癌的基因药物及其制备方法和用途
|
US8883493B2
(en)
|
2007-01-30 |
2014-11-11 |
Cedars-Sinai Medical Center |
Adenoviral vector comprising herpes simplex virus type 1 thymidine kinase and a transgene for increasing the expression of the transgene
|
AP2009005028A0
(en)
|
2007-04-10 |
2009-12-31 |
Univ Tulane |
Soluble and membrane-anchored forms of lassa virussubunit proteins
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
JP5737944B2
(ja)
|
2007-12-17 |
2015-06-17 |
ファイザー・リミテッドPfizer Limited |
間質性膀胱炎の治療
|
WO2009079649A1
(en)
|
2007-12-18 |
2009-06-25 |
Bioalliance C.V. |
Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
|
JP2011516078A
(ja)
|
2008-04-10 |
2011-05-26 |
セル・シグナリング・テクノロジー・インコーポレイテツド |
癌におけるegfr突然変異を検出する組成物および方法
|
WO2009150623A1
(en)
|
2008-06-13 |
2009-12-17 |
Pfizer Inc |
Treatment of chronic prostatitis
|
TR201815802T4
(tr)
|
2008-06-25 |
2018-11-21 |
Mesoblast Inc |
İnvertabral disklerin onarılması ve/veya yeniden yapılandırılması.
|
TWI516501B
(zh)
|
2008-09-12 |
2016-01-11 |
禮納特神經系統科學公司 |
Pcsk9拮抗劑類
|
KR102011609B1
(ko)
|
2008-11-20 |
2019-08-16 |
메소블라스트, 아이엔씨. |
췌장 기능장애를 치료 또는 예방하는 방법
|
BRPI1005670A8
(pt)
|
2009-01-05 |
2017-12-26 |
Epitogenesis Inc |
composições adjuvantes e processos de uso.
|
WO2010088560A1
(en)
|
2009-01-29 |
2010-08-05 |
University Of California, San Francisco |
Methods for distributing high levels of therapeutic agent throughout the cortex to treat neurological disorders
|
WO2010086828A2
(en)
|
2009-02-02 |
2010-08-05 |
Rinat Neuroscience Corporation |
Agonist anti-trkb monoclonal antibodies
|
US8568732B2
(en)
|
2009-03-06 |
2013-10-29 |
Novartis Ag |
Chlamydia antigens
|
WO2010118243A2
(en)
|
2009-04-08 |
2010-10-14 |
Genentech, Inc. |
Use of il-27 antagonists to treat lupus
|
CN109248313B
(zh)
|
2009-04-14 |
2023-01-17 |
葛兰素史密丝克莱恩生物有限公司 |
用于免疫接种以抵御金黄色葡萄球菌的组合物
|
MX356669B
(es)
|
2009-05-02 |
2018-06-08 |
Genzyme Corp |
Terapia genica para trastornos neurodegenerativos.
|
WO2010146511A1
(en)
|
2009-06-17 |
2010-12-23 |
Pfizer Limited |
Treatment of overactive bladder
|
MX2012000734A
(es)
|
2009-07-16 |
2012-01-27 |
Novartis Ag |
Inmunogenos destoxificados de escherichia coli.
|
GB0919690D0
(en)
|
2009-11-10 |
2009-12-23 |
Guy S And St Thomas S Nhs Foun |
compositions for immunising against staphylococcus aureus
|
TWI552760B
(zh)
|
2010-02-24 |
2016-10-11 |
雷那特神經科學股份有限公司 |
拮抗劑抗-il-7受體抗體及方法
|
GB201003333D0
(en)
|
2010-02-26 |
2010-04-14 |
Novartis Ag |
Immunogenic proteins and compositions
|
WO2011106705A2
(en)
|
2010-02-26 |
2011-09-01 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Dna-protein vaccination protocols
|
CA2792740A1
(en)
|
2010-03-11 |
2011-09-15 |
Rinat Neuroscience Corporation |
Antibodies with ph dependent antigen binding
|
GB201005625D0
(en)
|
2010-04-01 |
2010-05-19 |
Novartis Ag |
Immunogenic proteins and compositions
|
WO2011133931A1
(en)
|
2010-04-22 |
2011-10-27 |
Genentech, Inc. |
Use of il-27 antagonists for treating inflammatory bowel disease
|
JP5988961B2
(ja)
|
2010-04-28 |
2016-09-07 |
ザ ジェイ. デヴィッド グラッドストーン インスティテューツ |
心筋細胞を発生させるための方法
|
JP5926242B2
(ja)
|
2010-05-10 |
2016-05-25 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
エンドリボヌクレアーゼ組成物およびその使用方法
|
US20130150256A1
(en)
|
2010-06-11 |
2013-06-13 |
Jane Synnergren |
Novel micrornas for the detection and isolation of human embryonic stem cell-derived cardiac cell types
|
WO2012000065A1
(en)
|
2010-07-02 |
2012-01-05 |
Angioblast Systems, Inc. |
Treatment of t-cell mediated immune disorders
|
US8747844B2
(en)
|
2010-07-30 |
2014-06-10 |
Saint Louis University |
Methods of treating pain
|
US9132173B2
(en)
|
2010-10-15 |
2015-09-15 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Expression vector for cholesterol 24-hydrolase in therapy of Huntington's disease
|
WO2012075243A2
(en)
|
2010-12-01 |
2012-06-07 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for targeting sites of neovascular growth
|
WO2012072769A1
(en)
|
2010-12-01 |
2012-06-07 |
Novartis Ag |
Pneumococcal rrgb epitopes and clade combinations
|
EP2714058B1
(de)
|
2011-06-03 |
2018-12-19 |
Mesoblast, Inc. |
Verfahren zur behandlung der folgen eines schlaganfalls
|
CA2837651A1
(en)
|
2011-06-21 |
2012-12-27 |
Oncofactor Corporation |
Compositions and methods for the therapy and diagnosis of cancer
|
CN103717235A
(zh)
|
2011-06-24 |
2014-04-09 |
埃皮托吉尼西斯有限公司 |
作为抗原特异性免疫调节剂的包含选择的载体、维生素、单宁和类黄酮的组合的药物组合物
|
WO2013003899A1
(en)
|
2011-07-04 |
2013-01-10 |
Mesoblast, Inc |
Methods of treating or preventing rheumatic disease
|
US20130071375A1
(en)
|
2011-08-22 |
2013-03-21 |
Saint Louis University |
Compositions and methods for treating inflammation
|
WO2013028527A1
(en)
|
2011-08-23 |
2013-02-28 |
Indiana University Research And Technology Corporation |
Compositions and methods for treating cancer
|
CN108635377B
(zh)
|
2011-09-09 |
2022-06-24 |
麦瑟布莱斯特公司 |
增加成骨细胞功能的方法
|
AR088693A1
(es)
|
2011-11-11 |
2014-06-25 |
Rinat Neuroscience Corp |
Anticuerpos especificos para trop-2 y sus usos
|
CA2859364C
(en)
|
2011-12-16 |
2019-05-07 |
The Board Of Trustees Of The Leland Stanford Junior University |
Opsin polypeptides and methods of use thereof
|
BR112014014824A2
(pt)
|
2011-12-22 |
2019-09-24 |
Rinat Neuroscience Corp |
anticorpos antagonistas do receptor do hormônio de crescimento humano e métodos de uso dos mesmos
|
WO2013093693A1
(en)
|
2011-12-22 |
2013-06-27 |
Rinat Neuroscience Corp. |
Staphylococcus aureus specific antibodies and uses thereof
|
US10266850B2
(en)
|
2012-05-25 |
2019-04-23 |
The Regents Of The University Of California |
Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
|
AU2013290424B2
(en)
|
2012-07-19 |
2018-01-25 |
Redwood Bioscience, Inc. |
Antibody specific for CD22 and methods of use thereof
|
US8603470B1
(en)
|
2012-08-07 |
2013-12-10 |
National Cheng Kung University |
Use of IL-20 antagonists for treating liver diseases
|
BR112015003326A2
(pt)
|
2012-08-16 |
2017-07-04 |
Ipierian Inc |
métodos de tratamento de uma tauopatia
|
AU2013334229B2
(en)
|
2012-10-25 |
2018-02-15 |
Bioverativ Usa Inc. |
Anti-complement C1s antibodies and uses thereof
|
EP3906944A1
(de)
|
2012-11-02 |
2021-11-10 |
Bioverativ USA Inc. |
Anti-komplement-c1s-antikörper und verwendungen davon
|
RU2015115956A
(ru)
|
2012-11-09 |
2017-01-10 |
Пфайзер Инк. |
Антитела, специфичные в отношении фактора роста тромбоцитов в, и их композиции и применения
|
JP6340011B2
(ja)
|
2012-11-30 |
2018-06-06 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
シュードモナス抗原および抗原の組み合わせ
|
US20160175360A1
(en)
|
2012-12-12 |
2016-06-23 |
Mesoblast, Inc. |
Treatment of diseases of endothelial dysfunction and inflammation
|
EP3521420A1
(de)
|
2013-01-08 |
2019-08-07 |
Genzyme Corporation |
Verwendung von inos-inhibitoren zur erhöhung der viralen ausbeute in kulturen
|
US9066966B2
(en)
|
2013-02-01 |
2015-06-30 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Methods and pharmaceutical compositions for the treatment of cardiomyopathy due to friedreich ataxia
|
WO2014127148A1
(en)
|
2013-02-14 |
2014-08-21 |
The J. David Gladstone Institutes |
Compositions and methods of use thereof for identifying anti-viral agents
|
ES2758227T3
(es)
|
2013-02-15 |
2020-05-04 |
Univ California |
Receptor de antígeno quimérico y métodos de uso del mismo
|
EP2970945B1
(de)
|
2013-03-14 |
2024-05-01 |
GenVivo, Inc. |
Verbessertes thymidinkinasegen
|
IL292121B2
(en)
|
2013-03-15 |
2024-02-01 |
Takeda Pharmaceuticals Co |
Anti-plasma kallikrein antibodies
|
WO2014144844A1
(en)
|
2013-03-15 |
2014-09-18 |
The Board Of Trustees Of The Leland Stanford Junior University |
tRNA DERIVED SMALL RNAs (tsRNAs) INVOLVED IN CELL VIABILITY
|
US9644215B2
(en)
|
2013-04-12 |
2017-05-09 |
The General Hospital Corporation |
AAV1-caspase gene therapy induced pyroptosis for the treatment of tumors
|
MX2015014568A
(es)
|
2013-04-17 |
2016-12-02 |
Genzyme Corp |
Composiciones y metodos para tratar y prevenir la degeneracion macular.
|
SG11201508264UA
(en)
|
2013-05-07 |
2015-11-27 |
Rinat Neuroscience Corp |
Anti-glucagon receptor antibodies and methods of use thereof
|
PT3007726T
(pt)
|
2013-06-10 |
2020-06-22 |
Ipierian Inc |
Métodos de tratamento de uma tauopatia
|
JP6802063B2
(ja)
|
2013-06-25 |
2020-12-16 |
エピアクシス セラピューティクス プロプライエタリー リミテッド |
癌幹細胞を調節するための方法および組成物
|
EP3044314B1
(de)
|
2013-07-12 |
2019-04-10 |
SeNa Research, Inc. |
Verfahren und zusammensetzungen zur interferenz mit dna-polymerase und dna-synthese
|
US10208125B2
(en)
|
2013-07-15 |
2019-02-19 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Anti-mucin 1 binding agents and uses thereof
|
TWI623551B
(zh)
|
2013-08-02 |
2018-05-11 |
輝瑞大藥廠 |
抗cxcr4抗體及抗體-藥物結合物
|
WO2015031686A1
(en)
|
2013-08-30 |
2015-03-05 |
Amgen Inc. |
High titer recombinant aav vector production in adherent and suspension cells
|
SG11201601408PA
(en)
|
2013-09-18 |
2016-04-28 |
Univ Canberra |
Stem cell modulation ii
|
EP3066203B2
(de)
|
2013-11-05 |
2023-11-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Neues tiermodell für die alzheimer-krankheit
|
BR112016009797A2
(pt)
|
2013-11-13 |
2017-12-05 |
Bristol Myers Squibb Co |
anticorpos específicos de ligante 1a do tipo fator de necrose tumoral e composições e usos dos mesmos
|
US10172916B2
(en)
|
2013-11-15 |
2019-01-08 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods of treating heart failure with agonists of hypocretin receptor 2
|
CA2930877A1
(en)
|
2013-11-18 |
2015-05-21 |
Crispr Therapeutics Ag |
Crispr-cas system materials and methods
|
WO2015087187A1
(en)
|
2013-12-10 |
2015-06-18 |
Rinat Neuroscience Corp. |
Anti-sclerostin antibodies
|
EP3080266B1
(de)
|
2013-12-12 |
2021-02-03 |
The Regents of The University of California |
Verfahren und zusammensetzungen zur modifizierung einer einzelsträngigen zielnukleinsäure
|
WO2015109212A1
(en)
|
2014-01-17 |
2015-07-23 |
Pfizer Inc. |
Anti-il-2 antibodies and compositions and uses thereof
|
JP6719381B2
(ja)
|
2014-02-06 |
2020-07-08 |
ジェンザイム・コーポレーション |
黄斑変性を処置し、予防するための組成物および方法
|
WO2015124546A1
(en)
|
2014-02-19 |
2015-08-27 |
Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii- Cnic |
Aav vectors for the treatment of ischemic and non-ischemic heart disease
|
AU2015231231B2
(en)
|
2014-03-21 |
2021-09-02 |
The Board Of Trustees Of The Leland Stanford Junior University |
Genome editing without nucleases
|
PT3119431T
(pt)
|
2014-03-21 |
2024-04-16 |
Teva Pharmaceuticals Int Gmbh |
Anticorpos antagonistas dirigidos contra o peptídeo relacionado com o gene da calcitonina e métodos de utilização dos mesmos
|
WO2015168474A1
(en)
|
2014-04-30 |
2015-11-05 |
President And Fellows Of Harvard College |
Fusion proteins for treating cancer and related methods
|
US10329556B2
(en)
|
2014-05-13 |
2019-06-25 |
Bioatla, Llc |
Conditionally active biological proteins
|
AU2015277460B2
(en)
|
2014-06-18 |
2020-10-08 |
Albert Einstein College Of Medicine, Inc. |
Syntac polypeptides and uses thereof
|
US9840553B2
(en)
|
2014-06-28 |
2017-12-12 |
Kodiak Sciences Inc. |
Dual PDGF/VEGF antagonists
|
CA2994927A1
(en)
|
2014-08-08 |
2016-02-11 |
The Board Of Trustees Of The Leland Stanford Junior University |
High affinity pd-1 agents and methods of use
|
CN107106517A
(zh)
|
2014-08-25 |
2017-08-29 |
堪培拉大学 |
用于调节癌干细胞的组合物及其用途
|
JP7286267B2
(ja)
|
2014-08-28 |
2023-06-05 |
バイオアトラ インコーポレイテッド |
修飾t細胞に対する条件的活性型キメラ抗原受容体
|
US11111288B2
(en)
|
2014-08-28 |
2021-09-07 |
Bioatla, Inc. |
Conditionally active chimeric antigen receptors for modified t-cells
|
US10513699B2
(en)
|
2014-09-03 |
2019-12-24 |
Bioatla, Llc |
Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts
|
BR112017004675A2
(pt)
|
2014-09-09 |
2017-12-05 |
Unum Therapeutics |
receptores quiméricos e usos dos mesmos em terapia imunológica
|
TWI595006B
(zh)
|
2014-12-09 |
2017-08-11 |
禮納特神經系統科學公司 |
抗pd-1抗體類和使用彼等之方法
|
SI3233129T1
(sl)
|
2014-12-17 |
2020-07-31 |
Fundacion Para La Investigacion Medica Aplicada |
Konstrukti nukleinske kisline in vektorji genske terapije za uporabo pri zdravljenju Wilsonove bolezni in drugih stanj
|
CN107208105A
(zh)
|
2014-12-17 |
2017-09-26 |
基础应用医学研究基金会 |
用于治疗威尔森病的核酸构建体和基因治疗载体
|
EP3054006A1
(de)
|
2015-02-09 |
2016-08-10 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Reinigung von rekombinanten adeno-assoziierten viruspartikeln mittels mehrstufiger anionischer austauschchromatografie
|
EP3054007A1
(de)
|
2015-02-09 |
2016-08-10 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Reinigung von rekombinanten, adeno-assoziierten viren mit einem immunaffinen reinigungsschritt
|
JP6588995B2
(ja)
|
2015-03-13 |
2019-10-09 |
ザ ジャクソン ラボラトリーThe Jackson Laboratory |
三構成要素CRISPR/Cas複合体系およびその使用
|
EP3270897A4
(de)
|
2015-03-20 |
2018-12-05 |
The Regents Of The University Of Michigan |
Immunogene zusammensetzungen zur verwendung als impfstoff gegen bordetella
|
WO2016150964A1
(en)
|
2015-03-23 |
2016-09-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment and the prevention of neurological phenotype associated with friedreich ataxia
|
AU2016235163B2
(en)
|
2015-03-24 |
2022-03-24 |
The Regents Of The University Of California |
Adeno-associated virus variants and methods of use thereof
|
SG10201909180SA
(en)
|
2015-04-06 |
2019-11-28 |
Bioverativ Usa Inc |
Humanized anti-c1s antibodies and methods of use thereof
|
US9758575B2
(en)
|
2015-04-06 |
2017-09-12 |
Yung Shin Pharmaceutical Industrial Co. Ltd. |
Antibodies which specifically bind to canine vascular endothelial growth factor and uses thereof
|
JP6960396B2
(ja)
|
2015-04-07 |
2021-11-05 |
ザ ジェイ. デビッド グラッドストーン インスティテューツ、 ア テスタメンタリー トラスト エスタブリッシュド アンダー ザ ウィル オブ ジェイ. デビッド グラッドストーン |
分裂終了細胞の細胞分裂を誘発するための方法
|
US9969809B2
(en)
|
2015-04-13 |
2018-05-15 |
Pfizer Inc. |
Therapeutic antibodies and their uses
|
CN115141872A
(zh)
|
2015-05-05 |
2022-10-04 |
迈索布拉斯特国际有限公司 |
效能分析
|
EP3294755B1
(de)
|
2015-05-13 |
2023-08-23 |
The United States of America as represented by the Secretary of the Department of Health and Human Services |
Methoden und zusammensetzungen beruhend auf konstruktenenthaltend konservierte elemente zur induktion einer immunantwort
|
WO2016196366A1
(en)
|
2015-05-29 |
2016-12-08 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Extension of replicative lifespan in diseases of premature aging using p53 isoforms
|
WO2016196655A1
(en)
|
2015-06-03 |
2016-12-08 |
The Regents Of The University Of California |
Cas9 variants and methods of use thereof
|
EP3307391A1
(de)
|
2015-06-12 |
2018-04-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren und pharmazeutische zusammensetzung zur behandlung der alzheimer-krankheit
|
EP3313863B1
(de)
|
2015-06-29 |
2020-12-23 |
The Board of Trustees of the Leland Stanford Junior University |
Degronfusionskonstrukte und verfahren zur steuerung der proteinproduktion
|
EP3320101B1
(de)
|
2015-07-07 |
2021-08-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren und pharmazeutische zusammensetzungen zur expression eines polynukleotids von interesse im peripheren nervensystem einer person
|
US10877045B2
(en)
|
2015-07-21 |
2020-12-29 |
Saint Louis University |
Compositions and methods for diagnosing and treating endometriosis-related infertility
|
MX2018000714A
(es)
|
2015-07-21 |
2019-11-18 |
Dyax Corp |
Un inhibidor de anticuerpo monoclonal de factor xiia.
|
CA3025896A1
(en)
|
2015-07-23 |
2017-01-26 |
The Regents Of The University Of California |
Antibodies to coagulation factor xia and uses thereof
|
US11273167B2
(en)
|
2015-08-03 |
2022-03-15 |
The Regents Of The University Of California |
Compositions and methods for modulating ABHD2 activity
|
JP6664467B2
(ja)
|
2015-08-19 |
2020-03-13 |
ファイザー・インク |
組織因子経路インヒビター抗体およびその使用
|
ES2842306T3
(es)
|
2015-09-02 |
2021-07-13 |
Immutep Sas |
Anticuerpos anti LAG-3
|
CN113912718A
(zh)
|
2015-09-15 |
2022-01-11 |
供石公司 |
抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其用途
|
WO2017064546A1
(en)
|
2015-09-24 |
2017-04-20 |
Crispr Therapeutics Ag |
Novel family of rna-programmable endonucleases and their uses in genome editing and other applications
|
CN116712535A
(zh)
|
2015-10-16 |
2023-09-08 |
纽约市哥伦比亚大学理事会 |
用于抑制谱系特异性抗原的组合物和方法
|
JP7030689B2
(ja)
|
2015-10-23 |
2022-03-07 |
ファイザー インコーポレイティッド |
抗il-2抗体ならびにその組成物及び使用
|
WO2017075037A1
(en)
|
2015-10-27 |
2017-05-04 |
Scholar Rock, Inc. |
Primed growth factors and uses thereof
|
US10377801B2
(en)
|
2015-11-04 |
2019-08-13 |
Northwestern University |
Amelioration of chronic kidney disease
|
CN106699889A
(zh)
|
2015-11-18 |
2017-05-24 |
礼进生物医药科技(上海)有限公司 |
抗pd-1抗体及其治疗用途
|
US10669320B2
(en)
|
2015-11-18 |
2020-06-02 |
The Regents Of The University Of Michigan |
Mps1 and KNL1 phosphorylation system
|
WO2017096164A1
(en)
|
2015-12-02 |
2017-06-08 |
The Board Of Trustees Of The Leland Stanford Junior University |
Novel recombinant adeno-associated virus capsids with enhanced human skeletal muscle tropism
|
US10406244B2
(en)
|
2015-12-02 |
2019-09-10 |
The Board Of Trustees Of The Leland Stanford Junior University |
AAV vectors with expanded packaging capacity
|
RU2744860C2
(ru)
|
2015-12-30 |
2021-03-16 |
Кодиак Сайенсиз Инк. |
Антитела и их конъюгаты
|
CN116334113A
(zh)
|
2016-01-08 |
2023-06-27 |
加利福尼亚大学董事会 |
有条件活性的异二聚体多肽及其使用方法
|
ES2926977T3
(es)
|
2016-01-19 |
2022-10-31 |
Univ California |
Métodos para el tratamiento de la enfermedad de Danon y otros trastornos de autofagia
|
JP2019506398A
(ja)
|
2016-01-21 |
2019-03-07 |
ファイザー・インク |
上皮増殖因子受容体変異体iiiおよびcd3の単一および二重特異性抗体およびそれらの使用
|
CN109415704B
(zh)
|
2016-02-16 |
2022-02-25 |
利兰斯坦福初级大学董事会 |
对先已存在的人中和抗体有抗性的新型重组腺相关病毒衣壳
|
JP7372036B2
(ja)
|
2016-03-03 |
2023-10-31 |
キュー バイオファーマ, インコーポレイテッド |
T細胞調節多量体ポリペプチド及びその使用方法
|
MX2018011345A
(es)
|
2016-03-19 |
2019-05-27 |
F1 Oncology Inc |
Métodos y composiciones para transducir linfocitos y expansión regulada de los mismos.
|
US11325948B2
(en)
|
2016-03-19 |
2022-05-10 |
Exuma Biotech Corp. |
Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL
|
WO2020047527A2
(en)
|
2018-09-02 |
2020-03-05 |
F1 Bioventures, Llc |
Methods and compositions for genetically modifying lymphocytes in blood or in enriched pbmcs
|
US11111505B2
(en)
|
2016-03-19 |
2021-09-07 |
Exuma Biotech, Corp. |
Methods and compositions for transducing lymphocytes and regulating the activity thereof
|
CN109152821A
(zh)
|
2016-03-31 |
2019-01-04 |
星火治疗有限公司 |
基于柱的完全可扩展的rAAV制造工艺
|
IL295288B1
(en)
|
2016-04-04 |
2024-04-01 |
Bioverativ Usa Inc |
Anti-complement factor BB antibodies and their uses
|
TW201805307A
(zh)
|
2016-05-13 |
2018-02-16 |
美商拜奧亞特拉公司 |
抗-ror2抗體、抗體片段、其免疫結合物及其用途
|
KR20190019068A
(ko)
|
2016-05-18 |
2019-02-26 |
큐 바이오파마, 인크. |
T-세포 조절 다량체 폴리펩타이드 및 이의 사용 방법
|
CN109689096A
(zh)
|
2016-05-18 |
2019-04-26 |
阿尔伯特爱因斯坦医学院公司 |
变体pd-l1多肽、t细胞调节性多聚体多肽及其使用方法
|
AU2017292936C1
(en)
|
2016-07-08 |
2024-05-02 |
Exuma Biotech, Corp. |
Methods and compositions for transducing lymphocytes and regulating the activity thereof
|
US11285191B2
(en)
|
2016-07-26 |
2022-03-29 |
The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College |
Immunostimulatory compositions and uses therefor
|
CN109982710A
(zh)
|
2016-09-13 |
2019-07-05 |
杰克逊实验室 |
靶向增强的dna去甲基化
|
US10578610B2
(en)
|
2016-09-20 |
2020-03-03 |
Washington University |
Peptide regulators of mitochondrial fusion and methods of use
|
BR112019007309A2
(pt)
|
2016-10-12 |
2019-07-02 |
Bioverativ Usa Inc |
anticorpos anti-c1s e métodos de uso dos mesmos
|
US20180119141A1
(en)
|
2016-10-28 |
2018-05-03 |
Massachusetts Institute Of Technology |
Crispr/cas global regulator screening platform
|
US11332713B2
(en)
|
2016-11-16 |
2022-05-17 |
KSQ Therapeutics, Inc. |
Gene-regulating compositions and methods for improved immunotherapy
|
IL303806B1
(en)
|
2016-12-22 |
2024-01-01 |
Cue Biopharma Inc |
Multimeric polypeptides modulate T cells and methods for their use
|
WO2018129474A1
(en)
|
2017-01-09 |
2018-07-12 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides and methods of use thereof
|
EP3571294A1
(de)
|
2017-01-18 |
2019-11-27 |
F1 Oncology, Inc. |
Verfahren zur transduktion und expansion von immunzellen und verwendungen davon
|
CN110177808A
(zh)
|
2017-01-18 |
2019-08-27 |
F1肿瘤医学公司 |
针对axl或ror2的嵌合抗原受体及其使用方法
|
WO2018138360A1
(en)
|
2017-01-28 |
2018-08-02 |
Centro Nacional De Investigaciones Cardiovasculares Carlos Iii (F.S.P.) |
Oxygen carrying blood substitutes and their use as delivery vehicles
|
JP2020515284A
(ja)
|
2017-01-30 |
2020-05-28 |
ブレインヴェクティスBrainvectis |
ポリグルタミン反復脊髄小脳失調症の処置におけるコレステロール24−ヒドロキシラーゼ(hydrolase)のための発現ベクター
|
WO2018148246A1
(en)
|
2017-02-07 |
2018-08-16 |
Massachusetts Institute Of Technology |
Methods and compositions for rna-guided genetic circuits
|
SG11201907814SA
(en)
|
2017-03-03 |
2019-09-27 |
F1 Oncology Inc |
Methods and compositions for transducing and expanding lymphocytes and regulating the activity thereof
|
EP3589657A1
(de)
|
2017-03-03 |
2020-01-08 |
Rinat Neuroscience Corp. |
Anti-gitr-antikörper und verfahren zur verwendung davon
|
US20200056190A1
(en)
|
2017-03-16 |
2020-02-20 |
Pfizer Inc. |
Tyrosine prototrophy
|
US11510936B2
(en)
|
2017-03-24 |
2022-11-29 |
Inserm |
Methods and pharmaceutical composition for the treatment of neurodegenerative disease
|
CA3059938A1
(en)
|
2017-04-14 |
2018-10-18 |
Kodiak Sciences Inc. |
Complement factor d antagonist antibodies and conjugates thereof
|
US11773409B2
(en)
|
2017-04-21 |
2023-10-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
CRISPR/Cas 9-mediated integration of polynucleotides by sequential homologous recombination of AAV donor vectors
|
EP4137562A1
(de)
|
2017-05-04 |
2023-02-22 |
Mesoblast International Sàrl |
Mesenchymale linienvorläufer oder stammzellen mit erhöhter immunsuppression
|
TWI757499B
(zh)
|
2017-06-02 |
2022-03-11 |
美商輝瑞大藥廠 |
對flt3具特異性之抗體及其用途
|
CN111033631B
(zh)
|
2017-06-13 |
2024-03-12 |
波士顿基因公司 |
用于生成分子功能谱、对其进行可视化和分类的系统和方法
|
US20210228738A1
(en)
|
2017-07-17 |
2021-07-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
|
WO2019016784A1
(en)
|
2017-07-21 |
2019-01-24 |
Universidade De Coimbra |
ANTI-NUCLEOLIN ANTIBODIES
|
AU2018327224A1
(en)
|
2017-09-07 |
2020-04-23 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptide with conjugation sites and methods of use thereof
|
WO2019051122A2
(en)
|
2017-09-08 |
2019-03-14 |
Maverick Therapeutics, Inc. |
CONDITIONAL ACTIVATED BOND FRACTIONS CONTAINING FC REGIONS
|
CN111093715A
(zh)
|
2017-09-18 |
2020-05-01 |
儿童医院医疗中心 |
强绝缘子和其在基因递送中的用途
|
US20200271657A1
(en)
|
2017-10-04 |
2020-08-27 |
Opko Pharmaceuticals, Llc |
Articles and methods directed to personalized therapy of cancer
|
JP7369121B2
(ja)
|
2017-10-11 |
2023-10-25 |
バイオベラティブ・ユーエスエイ・インコーポレイテッド |
補体活性を誘発する方法
|
AU2018386301A1
(en)
|
2017-12-14 |
2020-06-18 |
Bayer Healthcare Llc |
Novel RNA-programmable endonuclease systems and their use in genome editing and other applications
|
WO2019139896A1
(en)
|
2018-01-09 |
2019-07-18 |
Cue Biopharma, Inc. |
Multimeric t-cell modulatory polypeptides and methods of use thereof
|
SG11202006883QA
(en)
|
2018-02-01 |
2020-08-28 |
Pfizer |
Chimeric antigen receptors targeting cd70
|
EP3746482A1
(de)
|
2018-02-01 |
2020-12-09 |
Pfizer Inc |
Für cd70 spezifische antikörper und ihre verwendungen
|
US11059876B2
(en)
|
2018-02-28 |
2021-07-13 |
Pfizer Inc. |
IL-15 variants and uses thereof
|
BR112020018620A2
(pt)
|
2018-03-15 |
2020-12-29 |
KSQ Therapeutics, Inc. |
Composições de regulação gênica e métodos para imunoterapia aprimorada
|
WO2019175380A2
(en)
|
2018-03-16 |
2019-09-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antigenic peptides deriving from secretogranin v and uses thereof for the diagnosis and treatment of type 1 diabetes
|
EP3765064A1
(de)
|
2018-03-16 |
2021-01-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Pcsk2-abgeleitete antigene peptide und verwendungen davon zur diagnose und behandlung von diabetes typ 1
|
WO2019175384A2
(en)
|
2018-03-16 |
2019-09-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antigenic peptides deriving from urocortin 3 and uses thereof for the diagnosis and treatment of type 1 diabetes
|
US20210054353A1
(en)
|
2018-03-19 |
2021-02-25 |
Crispr Therapeutics Ag |
Novel rna-programmable endonuclease systems and uses thereof
|
EP3774853A1
(de)
|
2018-03-30 |
2021-02-17 |
The Board of Trustees of the Leland Stanford Junior University |
Neuartige kapside des rekombinanten adeno-assoziierten virus mit erhöhtem menschlichem pankreatischem tropismus
|
WO2019219649A1
(en)
|
2018-05-14 |
2019-11-21 |
Vivet Therapeutics |
Gene therapy vectors comprising s/mar sequences
|
MX2020012607A
(es)
|
2018-05-23 |
2021-01-29 |
Pfizer |
Anticuerpos especificos para gucy2c y sus usos.
|
SG11202010580TA
(en)
|
2018-05-23 |
2020-12-30 |
Pfizer |
Antibodies specific for cd3 and uses thereof
|
SG11202100022SA
(en)
|
2018-07-12 |
2021-01-28 |
Rocket Pharmaceuticals Ltd |
Gene therapy vectors for treatment of danon disease
|
US20210309756A1
(en)
|
2018-08-09 |
2021-10-07 |
Maverick Therapeutics, Inc. |
Coexpression and purification method of conditionally activated binding proteins
|
BR112021003670A2
(pt)
|
2018-08-28 |
2021-05-18 |
Vor Biopharma, Inc. |
células-tronco hematopoéticas geneticamente modificadas e seus usos
|
CN113164556A
(zh)
|
2018-08-30 |
2021-07-23 |
特纳亚治疗股份有限公司 |
用心肌蛋白和ascl1进行的心脏细胞重编程
|
EP3863682B1
(de)
|
2018-10-12 |
2023-05-17 |
Vivet Therapeutics |
Codon-optimiertes transgen für die behandlung von progressiver familien intrahepatischer cholestase typ 3 (pfic3)
|
EP4205757A1
(de)
|
2018-10-29 |
2023-07-05 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Expressionsvektor für 24-hydrolase zur vorbeugung von amyotropher lateralsklerose
|
SG11202104634UA
(en)
|
2018-11-07 |
2021-06-29 |
Vivet Therapeutics |
Codon-optimized abcb11 transgene for the treatment of progressive familial intrahepatic cholestasis type 2 (pfic2)
|
TW202039542A
(zh)
|
2018-12-19 |
2020-11-01 |
美商庫爾生物製藥有限公司 |
多聚體t細胞調節多肽及其使用方法
|
SG11202106794WA
(en)
|
2019-01-02 |
2021-07-29 |
Mesoblast Int Sarl |
Method for treating lower back pain
|
KR20210110822A
(ko)
|
2019-01-03 |
2021-09-09 |
메조블라스트 인터내셔널 에스에이알엘 |
시력 향상을 위한 방법
|
AU2020231391A1
(en)
|
2019-03-05 |
2021-10-28 |
Takeda Pharmaceutical Company Limited |
Conditionally activated binding proteins containing Fc regions and moieties targeting tumor antigens
|
WO2020181062A1
(en)
|
2019-03-06 |
2020-09-10 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides and methods of use thereof
|
EP4219700A1
(de)
|
2019-03-07 |
2023-08-02 |
The Regents of the University of California |
Crispr-cas-effektorpolypeptide und verfahren zur verwendung davon
|
EP3937963A2
(de)
|
2019-03-12 |
2022-01-19 |
CRISPR Therapeutics AG |
Neuartige rna-programmierbare high-fidelity-endonukleasesysteme und verwendungen davon
|
US20220154153A1
(en)
|
2019-03-22 |
2022-05-19 |
Université de Paris |
New inhibitors of lrrk2/pp1 interaction
|
JP2022527860A
(ja)
|
2019-04-02 |
2022-06-06 |
ケンジョッケティ バイオテクノロジー,インク. |
排出ポンプ-癌抗原マルチ特異性抗体ならびにそれに関する組成物、試薬、キットおよび方法
|
EP3972631A2
(de)
|
2019-05-21 |
2022-03-30 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Expressionsvektor für cholesterin-24-hydrolase in der therapie des rett-syndroms
|
AU2020277691A1
(en)
|
2019-05-23 |
2021-12-23 |
Mesoblast International Sarl |
Functional recovery from cerebral infarction
|
JP2022544740A
(ja)
|
2019-07-02 |
2022-10-21 |
フンダシオン・パラ・ラ・インベスティガシオン・メディカ・アプリカダ |
cPLA2e誘導剤及びその使用
|
US20210005283A1
(en)
|
2019-07-03 |
2021-01-07 |
Bostongene Corporation |
Techniques for bias correction in sequence data
|
WO2021005223A1
(en)
|
2019-07-10 |
2021-01-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of epilepsy
|
EP3997226A1
(de)
|
2019-07-11 |
2022-05-18 |
Tenaya Therapeutics, Inc. |
Umprogrammierung von herzzellen mit mikrornas und anderen faktoren
|
EP4003508A1
(de)
|
2019-07-31 |
2022-06-01 |
Memorial Sloan Kettering Cancer Center |
Perfusionsmodulierte tumordosismodellierung mit einzeldosis-strahlentherapie
|
CA3153932A1
(en)
|
2019-10-07 |
2021-04-15 |
Jonathan Kipnis |
Modulating lymphatic vessels in neurological disease
|
CA3157509A1
(en)
|
2019-10-10 |
2021-04-15 |
Kodiak Sciences Inc. |
Methods of treating an eye disorder
|
US20240092935A1
(en)
|
2019-10-11 |
2024-03-21 |
Beth Israel Deaconess Medical Center, Inc. |
Anti-tn antibodies and uses thereof
|
US20230016983A1
(en)
|
2019-11-19 |
2023-01-19 |
lNSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) |
Antisense oligonucleotides and thier use for the treatment of cancer
|
WO2021113736A1
(en)
|
2019-12-05 |
2021-06-10 |
Massachusetts Institute Of Technology |
Single-domain antibody to chloramphenicol
|
EP4093426A1
(de)
|
2020-01-24 |
2022-11-30 |
University of Virginia Patent Foundation |
Modulation von lymphgefässen bei neurologischen erkrankungen
|
WO2021154079A1
(en)
|
2020-01-29 |
2021-08-05 |
Rijksuniversiteit Groningen |
Means and methods for modulating lipid metabolism
|
WO2021173965A1
(en)
|
2020-02-28 |
2021-09-02 |
Massachusetts Institute Of Technology |
Identification of variable influenza residues and uses thereof
|
US20230103731A1
(en)
|
2020-03-02 |
2023-04-06 |
Tenaya Therapeutics, Inc. |
Gene vector control by cardiomyocyte-expressed micrornas
|
WO2021205325A1
(en)
|
2020-04-08 |
2021-10-14 |
Pfizer Inc. |
Anti-gucy2c antibodies and uses thereof
|
EP4146688A1
(de)
|
2020-05-06 |
2023-03-15 |
CRISPR Therapeutics AG |
Maskenpeptide und maskierte anti-ptk7-antikörper damit
|
KR20230042222A
(ko)
|
2020-05-26 |
2023-03-28 |
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) |
중증 급성 호흡기 증후군 코로나바이러스 2(sars-cov-2) 폴리펩티드 및 백신 목적을 위한 이의 용도
|
EP4161564A1
(de)
|
2020-06-04 |
2023-04-12 |
Kenjockety Biotechnology, Inc. |
Multispezifische antikörper gegen abcg2-effluxpumpen-krebsantigen und zusammensetzungen, reagenzien, kits und verfahren im zusammenhang damit
|
EP4162048A1
(de)
|
2020-06-09 |
2023-04-12 |
Genethon |
Behandlung von genetischen dilatierten kardiomyopathien
|
WO2021250079A1
(en)
|
2020-06-09 |
2021-12-16 |
Genethon |
Cilp-1 inhibitors for use in the treatment of dilated cardiomyopathies
|
CN116322790A
(zh)
|
2020-06-09 |
2023-06-23 |
吉尼松公司 |
用于治疗扩张型心肌病的nrf2激活剂
|
CA3177613A1
(en)
|
2020-07-10 |
2022-04-13 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and compositions for treating epilepsy
|
JP2023533793A
(ja)
|
2020-07-17 |
2023-08-04 |
ファイザー・インク |
治療用抗体およびそれらの使用
|
JP2023535604A
(ja)
|
2020-07-30 |
2023-08-18 |
ファイザー・インク |
遺伝子複製を有する細胞およびその使用
|
WO2022029322A2
(en)
|
2020-08-06 |
2022-02-10 |
Fundacion Para La Investigacion Medica Aplicada |
Viral particles for use in treating tauopathies such as alzheimer's diseases by gene therapy
|
EP4176058A1
(de)
|
2020-08-07 |
2023-05-10 |
The Jackson Laboratory |
Zusammensetzungen und verfahren zur gezielten sequenzinsertion
|
IL300263A
(en)
|
2020-08-07 |
2023-03-01 |
Spacecraft Seven Llc |
Plakophilin-2 (PKP2) gene therapy using an AAV vector
|
US20230265456A1
(en)
|
2020-08-10 |
2023-08-24 |
Fundacion Para La Investigacion Medica Aplicada |
Gene therapy vector expressing cyp27a1 for the treatment of cerebrotendinous xanthomatosis
|
CA3200563A1
(en)
|
2020-09-29 |
2022-04-07 |
Genethon |
Enhancing utrophin expression in cell by inducing mutations within utrophin regulatory elements and therapeutic use thereof
|
US11781156B2
(en)
|
2020-10-09 |
2023-10-10 |
Tenaya Therapeutics, Inc. |
Plakophillin-2 gene therapy methods and compositions
|
CN116390935A
(zh)
|
2020-10-09 |
2023-07-04 |
Ucb生物制药有限责任公司 |
核酸构建体、病毒载体和病毒颗粒
|
WO2022101463A1
(en)
|
2020-11-16 |
2022-05-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of the last c-terminal residues m31/41 of zikv m ectodomain for triggering apoptotic cell death
|
WO2022120256A2
(en)
|
2020-12-04 |
2022-06-09 |
Bostongene Corporation |
Hierarchical machine learning techniques for identifying molecular categories from expression data
|
WO2022136616A1
(en)
|
2020-12-23 |
2022-06-30 |
Vivet Therapeutics |
Minimal bile acid inducible promoters for gene therapy
|
WO2022187289A1
(en)
|
2021-03-01 |
2022-09-09 |
Exuma Biotech Corp. |
Methods and compositions for the delivery of retroviral particles
|
US20220372580A1
(en)
|
2021-04-29 |
2022-11-24 |
Bostongene Corporation |
Machine learning techniques for estimating tumor cell expression in complex tumor tissue
|
WO2022259190A1
(en)
|
2021-06-10 |
2022-12-15 |
Janssen Biotech, Inc. |
Nucleic acid coding for klk2-gpi fusion protein, recombinant cells, and uses thereof
|
EP4352214A1
(de)
|
2021-06-11 |
2024-04-17 |
Bayer AG |
Typ-v-rna-programmierbare endonukleasesysteme
|
EP4101928A1
(de)
|
2021-06-11 |
2022-12-14 |
Bayer AG |
Programmierbare typ-v-rna-endonukleasesysteme
|
CA3227875A1
(en)
|
2021-08-02 |
2023-02-09 |
Pfizer Inc. |
Improved expression vectors and uses thereof
|
WO2023012165A1
(en)
|
2021-08-02 |
2023-02-09 |
Universite De Montpellier |
Compositions and methods for treating cmt1a or cmt1e diseases with rnai molecules targeting pmp22
|
EP4144841A1
(de)
|
2021-09-07 |
2023-03-08 |
Bayer AG |
Neue programmierbare rna-endonuklease-systeme mit verbesserter pam-spezifität und deren verwendung
|
AU2022349103A1
(en)
|
2021-09-27 |
2024-03-28 |
Sotio Biotech Inc. |
Chimeric receptor polypeptides in combination with trans metabolism molecules that re-direct glucose metabolites out of the glycolysis pathway and therapeutic uses thereof
|
WO2023070072A1
(en)
|
2021-10-21 |
2023-04-27 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Retroelement-generated transcription factor decoys
|
AR127455A1
(es)
|
2021-10-28 |
2024-01-24 |
UCB Biopharma SRL |
Constructos de ácido nucleico, vectores víricos y partículas víricas
|
WO2023081756A1
(en)
|
2021-11-03 |
2023-05-11 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Precise genome editing using retrons
|
WO2023091909A1
(en)
|
2021-11-16 |
2023-05-25 |
Sotio Biotech Inc. |
Treatment of myxoid/round cell liposarcoma patients
|
WO2023102388A1
(en)
|
2021-11-30 |
2023-06-08 |
Sanofi Pasteur Inc. |
Human metapneumovirus viral vector-based vaccines
|
WO2023114658A1
(en)
|
2021-12-13 |
2023-06-22 |
Kenjockety Biotechnology, Inc. |
Anti-abcb1 antibodies
|
WO2023118068A1
(en)
|
2021-12-23 |
2023-06-29 |
Bayer Aktiengesellschaft |
Novel small type v rna programmable endonuclease systems
|
WO2023141602A2
(en)
|
2022-01-21 |
2023-07-27 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
US20230245479A1
(en)
|
2022-01-31 |
2023-08-03 |
Bostongene Corporation |
Machine learning techniques for cytometry
|
WO2023150563A1
(en)
|
2022-02-01 |
2023-08-10 |
Cornell University |
Methods and pharmaceutical compositions for the treatment and the prevention of cardiomyopathy associated with friedreich ataxia
|
WO2023148598A1
(en)
|
2022-02-02 |
2023-08-10 |
Pfizer Inc. |
Cysteine prototrophy
|
WO2023159220A1
(en)
|
2022-02-18 |
2023-08-24 |
Kenjockety Biotechnology, Inc. |
Anti-cd47 antibodies
|
WO2023168305A1
(en)
|
2022-03-01 |
2023-09-07 |
Exuma Biotech Corp. |
Viral particles with membrane-bound hyaluronidase
|
WO2023183588A1
(en)
|
2022-03-25 |
2023-09-28 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Methods of assessing engineered retron activity, and uses thereof
|
WO2023183627A1
(en)
|
2022-03-25 |
2023-09-28 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Production of reverse transcribed dna (rt-dna) using a retron reverse transcriptase from exogenous rna
|
WO2023183589A1
(en)
|
2022-03-25 |
2023-09-28 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Rt-dna fidelity and retron genome editing
|
WO2023237587A1
(en)
|
2022-06-10 |
2023-12-14 |
Bayer Aktiengesellschaft |
Novel small type v rna programmable endonuclease systems
|
EP4299739A1
(de)
|
2022-06-30 |
2024-01-03 |
Inari Agriculture Technology, Inc. |
Zusammensetzungen und verfahren zur genomeditierung
|
WO2024005863A1
(en)
|
2022-06-30 |
2024-01-04 |
Inari Agriculture Technology, Inc. |
Compositions, systems, and methods for genome editing
|
EP4299733A1
(de)
|
2022-06-30 |
2024-01-03 |
Inari Agriculture Technology, Inc. |
Zusammensetzungen, systeme und verfahren zum genomeditieren
|
WO2024005864A1
(en)
|
2022-06-30 |
2024-01-04 |
Inari Agriculture Technology, Inc. |
Compositions, systems, and methods for genome editing
|
WO2024011237A1
(en)
|
2022-07-08 |
2024-01-11 |
Cornell University |
Methods and pharmaceutical compositions for the treatment and the prevention of alzheimers disease
|
US20240029884A1
(en)
|
2022-07-15 |
2024-01-25 |
Bostongene Corporation |
Techniques for detecting homologous recombination deficiency (hrd)
|
WO2024020346A2
(en)
|
2022-07-18 |
2024-01-25 |
Renagade Therapeutics Management Inc. |
Gene editing components, systems, and methods of use
|
WO2024017990A1
(en)
|
2022-07-21 |
2024-01-25 |
Institut National de la Santé et de la Recherche Médicale |
Methods and compositions for treating chronic pain disorders
|
WO2024040207A1
(en)
|
2022-08-19 |
2024-02-22 |
Sotio Biotech Inc. |
Genetically engineered natural killer (nk) cells with chimeric receptor polypeptides in combination with trans metabolism molecules and therapeutic uses thereof
|
WO2024040208A1
(en)
|
2022-08-19 |
2024-02-22 |
Sotio Biotech Inc. |
Genetically engineered immune cells with chimeric receptor polypeptides in combination with multiple trans metabolism molecules and therapeutic uses thereof
|
WO2024044673A1
(en)
|
2022-08-24 |
2024-02-29 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Dual cut retron editors for genomic insertions and deletions
|
WO2024044659A1
(en)
|
2022-08-24 |
2024-02-29 |
Tectonic Therapeutic, Inc. |
Constitutively active g protein-coupled receptor compositions and methods of use thereof
|
WO2024044723A1
(en)
|
2022-08-25 |
2024-02-29 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
WO2024068996A1
(en)
|
2022-09-30 |
2024-04-04 |
Centre Hospitalier Universitaire Vaudois (C.H.U.V.) |
Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
|
WO2024079317A1
(en)
|
2022-10-14 |
2024-04-18 |
Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical composition for the treatment of alpha-synucleinopathies
|